The gut microbiome dysbiosis and regulation by fecal microbiota transplantation: umbrella review
2023
Xianzhuo Zhang | Xufei Luo | Liang Tian | Ping Yue | Mengyao Li | Kefeng Liu | Daoming Zhu | Chongfei Huang | Qianling Shi | Liping Yang | Zhili Xia | Jinyu Zhao | Zelong Ma | Jianlong Li | Joseph W. Leung | Yanyan Lin | Jinqiu Yuan | Wenbo Meng | Xun Li | Yaolong Chen | Yaolong Chen | Yaolong Chen | Yaolong Chen
BackgroundGut microbiome dysbiosis has been implicated in various gastrointestinal and extra-gastrointestinal diseases, but evidence on the efficacy and safety of fecal microbiota transplantation (FMT) for therapeutic indications remains unclear.MethodsThe gutMDisorder database was used to summarize the associations between gut microbiome dysbiosis and diseases. We performed an umbrella review of published meta-analyses to determine the evidence synthesis on the efficacy and safety of FMT in treating various diseases. Our study was registered in PROSPERO (CRD42022301226).ResultsGut microbiome dysbiosis was associated with 117 gastrointestinal and extra-gastrointestinal. Colorectal cancer was associated with 92 dysbiosis. Dysbiosis involving Firmicutes (phylum) was associated with 34 diseases. We identified 62 published meta-analyses of FMT. FMT was found to be effective for 13 diseases, with a 95.56% cure rate (95% CI: 93.88–97.05%) for recurrent Chloridoids difficile infection (rCDI). Evidence was high quality for rCDI and moderate to high quality for ulcerative colitis and Crohn’s disease but low to very low quality for other diseases.ConclusionGut microbiome dysbiosis may be implicated in numerous diseases. Substantial evidence suggests FMT improves clinical outcomes for certain indications, but evidence quality varies greatly depending on the specific indication, route of administration, frequency of instillation, fecal preparation, and donor type. This variability should inform clinical, policy, and implementation decisions regarding FMT.
显示更多 [+] 显示较少 [-]